Shares of Affirmed Therapeutics BV (NASDAQ:AFMD) dropped 6.1% during mid-day trading on Wednesday . The stock traded as low as $2.60 and last traded at $2.61, with a volume of 99,636 shares changing hands. The stock had previously closed at $2.78.

AFMD has been the topic of several recent research reports. Leerink Swann raised Affirmed Therapeutics BV from a “market perform” rating to an “outperform” rating in a research note on Monday, July 18th. Wells Fargo & Co. reaffirmed a “buy” rating on shares of Affirmed Therapeutics BV in a research report on Wednesday, May 18th. Finally, Jefferies Group reaffirmed a “hold” rating on shares of Affirmed Therapeutics BV in a research report on Tuesday, August 9th. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the stock. The stock has an average rating of “Buy” and a consensus price target of $8.63.

The company has a 50-day moving average price of $2.83 and a 200-day moving average price of $3.41. The firm’s market capitalization is $84.72 million.

Affirmed Therapeutics BV (NASDAQ:AFMD) last issued its quarterly earnings results on Wednesday, August 10th. The biopharmaceutical company reported ($0.27) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.22) by $0.05. The business had revenue of $2.07 million for the quarter, compared to analyst estimates of $2.10 million. The company’s revenue was down 6.4% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.19) earnings per share. On average, equities analysts forecast that Affirmed Therapeutics BV will post ($1.13) EPS for the current fiscal year.

Affimed N.V. is a clinical-stage biopharmaceutical company focused on discovering and developing cancer immunotherapies. The Company’s product candidates are developed in the field of immuno-oncology, which represents an approach to cancer research that seeks to harness the body’s own immune system to fight tumor cells.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.